Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Infanrix Combination Vaccine BLA Needs More U.S. Immunogenicity Data

Executive Summary

Additional U.S. immunogenicity data should be collected on GlaxoSmithKline's Infanrix combination vaccine through a head-to-head comparison to the separately administered components, FDA's Vaccines & Related Biological Products Advisory Committee recommended March 7.

You may also be interested in...



Pediarix Simplifies Vaccine Schedule; Prevnar Labeling Update Due In 2003

GlaxoSmithKline will update Pediarix labeling to include more information about co-administration with Wyeth's Prevnar before the end of the 2003

Pediarix Simplifies Vaccine Schedule; Prevnar Labeling Update Due In 2003

GlaxoSmithKline will update Pediarix labeling to include more information about co-administration with Wyeth's Prevnar before the end of the 2003

GSK Has Generalized Anxiety For Paxil, Augmented Patent For Augmentin

GlaxoSmithKline is initiating direct-to-consumer advertising to support Paxil for generalized anxiety disorder to coincide with the market entrance of the first generic versions of Prozac.

Related Content

UsernamePublicRestriction

Register

PS037476

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel